Roche announces positive results for Actemra in phase III study

VIENNA Nov 13 Reuters Swiss drugmaker Roche said on Sunday its rheumatoid arthritis medication Actemra forgiant cell arteritis showed to be superior to steroids alone inmaintaining steroidfree remiss…
Read the full story: Bioportfolio Latest News